Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Pfizer Inc. (NYSE:PFE) have earned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $34.54.

A number of analysts have commented on the stock. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, September 16th. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st.

Institutional Trading of Pfizer

Several institutional investors have recently added to or reduced their stakes in PFE. Olistico Wealth LLC purchased a new position in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer during the 2nd quarter valued at about $29,000. Quarry LP acquired a new position in Pfizer in the 2nd quarter valued at about $31,000. Creekmur Asset Management LLC purchased a new stake in Pfizer during the fourth quarter worth about $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $29.52 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock’s 50 day simple moving average is $29.36 and its 200-day simple moving average is $28.28. The company has a market cap of $167.25 billion, a PE ratio of -491.83, a price-to-earnings-growth ratio of 1.05 and a beta of 0.68. Pfizer has a 1-year low of $25.20 and a 1-year high of $34.11.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm posted $0.67 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer will post 2.66 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.